Key result
Gut microbiome influences cardiovascular health via TMAO and SCFAs, highlighting potential for microbiome-targeted therapies.
Why the study?
The gut microbiome influences cardiovascular disease pathophysiology, but clinical translation and standardized microbiome-based therapies remain challenging.
The gut microbiome and its metabolites significantly influence cardiovascular disease pathophysiology, presenting a potential target for future customized microbiome-based therapies.
Answers are grounded in this paper and cite their sources.
Does not yet support microbiome-targeted therapies in routine care; leaves open their efficacy pending randomized trials.
The gut-heart connection has emerged as a significant area of research, revealing how gut microbiota influences cardiovascular disease (CVD) pathophysiology. The gut microbiota has a significant impact on cardiovascular health through its involvement in endothelial function, systemic inflammation, cholesterol metabolism, and metabolic balance. Atherosclerosis, hypertension, myocardial infarction, and heart failure have all been linked to dysbiosis, an imbalance in the makeup of microorganisms. Important metabolites produced by microorganisms have a direct effect on vascular integrity, thrombosis risk, and lipid metabolism. These include trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and secondary bile acids. There is potential for lowering the risk of CVD by addressing the gut microbiota through dietary changes, probiotics, prebiotics, and customized microbiome-based therapies. Implementing microbiome-based cardiovascular therapy is still hampered by differences in gut microbiota makeup, difficulties with clinical translation, and the requirement for standardized procedures. This review examines existing treatment approaches, future directions in microbiome research, and the processes underpinning the gut microbiome's influence on CVD. Establishing microbiome-targeted therapies in clinical cardiology requires extensive, long-term research incorporating multi-omics techniques.
No takes yet. Share an insight, caveat, or question.
Sanat Mahendra Dhoke (2025) conducted a review in Cardiovascular disease. Microbiome-targeted therapies was evaluated. The gut microbiome significantly influences cardiovascular health through microbial metabolites like TMAO and SCFAs, highlighting the potential of microbiome-targeted therapies for cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: